Keyword: Boehringer Ingelheim
Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.
BI 409306 failed to show superiority over placebo in cognition across a midphase program that enrolled 457 patients with early signs of Alzheimer’s.
Bob Hugin retires from Celgene, Voyager founder steps down as CEO, Boehringer named new U.S. chief to replace retiring Fonteyne.
Sanofi’s €45-a-share cash bid enabled it to leapfrog Novo Nordisk in the race to buy Ablynx and land its second big-ticket takeover of the month.
The agreement tasks Adimab with turning its yeast-based antibody discovery platform against multiple targets picked out by Boehringer.
The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.
Boehringer Ingelheim is deepening its venture fund pockets from €100 million to €250 million as it looks to change up its investment strategy.
Centrexion will use the cash to move nonopioid pain drug CNTX-4975 into a phase 3 trial in patients with knee osteoarthritis in the coming months.